Abstract
Background There is large body of evidence on the correlation between chronic inflammatory diseases like rheumatoid arthritis (RA) and increased risk of cardiovascular diseases (CVD). Chronic inflammation is an independent risk factor for the development of early atherosclerosis. The possible role of anti TNFa biologic drugs in reducing this risk arouses great interest among the scientific community. Many studies indicate the possibility that anti-TNF-a agents may reduce CVD risk and mortality in adult RA patients. There are only few data about the pediatric population.
Highlights
There is large body of evidence on the correlation between chronic inflammatory diseases like rheumatoid arthritis (RA) and increased risk of cardiovascular diseases (CVD)
Many studies indicate the possibility that anti-TNF-a agents may reduce CVD risk and mortality in adult RA patients
During the study all biomarkers of endothelial dysfunction progressively improved after 1 year of etanercept treatment in juvenile idiopathic arthritis (JIA) children
Summary
There is large body of evidence on the correlation between chronic inflammatory diseases like rheumatoid arthritis (RA) and increased risk of cardiovascular diseases (CVD). Chronic inflammation is an independent risk factor for the development of early atherosclerosis. The possible role of anti TNF- a biologic drugs in reducing this risk arouses great interest among the scientific community. Many studies indicate the possibility that anti-TNF-a agents may reduce CVD risk and mortality in adult RA patients. There are only few data about the pediatric population
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
